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Abstract
Background: While vancomycin loading doses may facilitate earlier pharmacokinetic–
pharmacodynamic target attainment, the impact of loading doses on clinical outcomes
remains understudied. Critically ill patients are at highest risk of morbidity and mortality from
methicillin resistant Staphylococcus aureus (MRSA) infection and hypothesized to most likely
benefit from a loading dose. We sought to determine the association between receipt of a
vancomycin loading dose and clinical outcomes in a cohort of critically ill adults.
Methods: Four hundred and forty-nine critically ill patients with MRSA cultures isolated
from blood or respiratory specimens were eligible for the study. Cohorts were established
by receipt of a loading dose (⩾20 mg/kg actual body weight) or not. The primary outcome
was clinical failure, a composite outcome of death within 30 days of first MRSA culture, blood
cultures positive ⩾7 days, white blood cell count up to 5 days from vancomycin initiation,
temperature up to 5 days from vancomycin initiation, or substitution (or addition) of another
MRSA agent.
Results: There was no difference in the percentage of patients experiencing clinical failure
between the loading dose and no loading dose groups (74.8% versus 72.8%; p = 0.698).
Secondary outcomes were also similar between groups, including mortality and acute kidney
injury, as was subgroup analysis based on site of infection. Exploratory analyses, including
assessment of loading dose based on quartiles and a multivariable logistic regression model
showed no differences.
Conclusion: Use of vancomycin loading doses was not associated with improved clinical
outcomes in critically ill patients with MRSA infection.
Keywords: critical care, infection, loading dose, methicillin resistant Staphylococcus aureus
(MRSA), vancomycin
Received: 17 December 2020; revised manuscript accepted: 8 March 2021.

Introduction
Methicillin-resistant Staphylococcus aureus (MRSA)
is a significant pathogen in critically ill patients.
In a nationwide surveillance study of United
States hospitals, S. aureus was responsible for
20% of nosocomial bloodstream infections, with

an alarming increase in MRSA isolates more than
doubling from 22% to 57% over the period from
1995 to 2001.1 In critically ill patients, MRSA
bacteremia is associated with a 22.1% higher
attributable mortality rate compared with methicillin-sensitive S. aureus.2 S. aureus is isolated in
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approximately one out of every five cases of ventilator-associated pneumonia, with approximately
56% MRSA isolates.3
Recent data suggest that inadequate attainment of
a therapeutic vancomycin area-under-the-curve
(AUC) to minimum inhibitory concentration
(MIC) ratio on days 1 and 2 of therapy in MRSA
bacteremia is associated with treatment failure.4
Critically ill patients commonly receive significant
fluid resuscitation and experience fluid shifts from
the intravascular to the extravascular compartment, which increases the volume of distribution
(Vd) for hydrophilic drugs such as vancomycin.5,6
Accordingly, recently updated consensus guidelines on vancomycin state that a loading dose of
20–35 mg/kg actual body weight (not to exceed
3000 mg) can be considered for critically ill patients
with suspected or confirmed MRSA infection in
order to ensure rapid attainment of appropriate
serum concentrations.7 However, this recommendation is limited by moderate strength of recommendation (B) and quality of evidence (II), and is
primarily based on pharmacokinetic outcomes
rather than a documented clinical benefit.7
In a recent survey of practitioners regarding vancomycin dosing in critically ill patients assessing
self-reported consensus guideline compliance, use
of loading doses for a variety of clinical scenarios
was highly variable, with respondents often citing
the lack of evidence for the clinical decision to
forgo a loading dose, followed by concerns of
nephrotoxicity.8 Given that critically ill patients
are particularly vulnerable to poor outcomes from
MRSA infection and exhibit altered pharmacokinetics of vancomycin that may place them at risk
of missing identified pharmacokinetic–pharmacodynamic targets, they are logically the population
to gain the most benefit from loading doses of
vancomycin. As such, we sought to determine
whether critically ill patients with MRSA infection
demonstrated improved clinical outcomes when
receiving vancomycin loading doses (versus not) in
order to provide needed clinical data to augment
the pharmacokinetic outcomes previously assessed
in studies of vancomycin loading doses.
Material and methods
Study design
This was a single center, retrospective cohort
study of critically ill patients admitted to any
2

intensive care unit (ICU) from January 2008 to
October 2016 within a 865-bed tertiary academic
medical center that serves as a referral center for
the state and surrounding regions. Patients were
included in the study if they had a positive respiratory or blood culture for MRSA and had vancomycin initiated for MRSA during or up to 48 h
before an ICU admission. Exclusion criteria were
as follows: weight ⩾125 kg, any MRSA culture
other than from blood or respiratory source,
<1000 colony forming units/ml or 1–2% MRSA
on respiratory cultures, loading dose information
missing (i.e. from outside hospital), or if vancomycin was started >48 h prior to the ICU admission. We elected to study pneumonia and
bacteremia given the frequency of these infections
in critically ill patients and their relative degree of
morbidity compared with other infections (i.e.
skin and soft tissue) in an attempt to prognostically enrich the study for patients that might clinically benefit from a loading dose of vancomycin.9
A weight of ⩾125 kg was excluded so as not to
confound the assessment of loading doses on a
milligram per kilogram of actual body weight
basis. Patients were classified into two cohorts
based on their initial vancomycin dose received:
loading dose (⩾20 mg/kg actual body weight) or
no loading dose (<20 mg/kg actual body weight).
The primary outcome was clinical failure, defined
as a composite outcome with similar definitions
to prior studies of MRSA infection,10,11 which
included: death within 30 days of first MRSA culture, blood cultures positive ⩾7 days, white blood
cell (WBC) count >12 × 103/mm3 up to 5 days
from
vancomycin
initiation,
temperature
>100.4°F up to 5 days from vancomycin initiation, or substitution (or addition) of another targeted anti-MRSA antibiotic such as daptomycin,
linezolid, or ceftaroline. The primary outcome
was adjudicated in the order of the outcomes
stated above, thus while some patients may have
had more than one definition of clinical failure,
each patient was classified with only one of the
definitions based on the sequential order assessed.
Secondary outcomes included all-cause mortality
in the ICU, time from vancomycin initiation to
ICU discharge, acute kidney injury (AKI) within
5 days of vancomycin initiation as assessed by the
serum creatinine component of the Kidney
Disease Improving Global Outcomes criteria,12
first vancomycin serum trough concentration, and
duration of vasopressor support, if applicable.
journals.sagepub.com/home/tai
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Data were extracted from the electronic data
warehouse and manual chart review was performed on all included patients to ensure integrity
of the data. Data were collected on patients to
ensure comparability at baseline, including potential factors hypothesized by the investigators as
being associated with receipt of a loading dose
including severity of illness assessments such as
Sequential Organ Failure Assessment score
(SOFA)13 and Pitt bacteremia score (PBS),14,15
need for mechanical ventilation or vasopressor
support at the time of vancomycin initiation, hospital service (classified into medical or surgical
ICUs), history of kidney disease, and kidney function at the time of vancomycin initiation.
Vancomycin MICs were determined per Clinical
and Laboratory Standards Institute standards by
broth microdilution via automated susceptibility
testing methods with the Phoenix™ Automated
Microbiology System (BD Diagnostics, Sparks,
MD, USA) from January 2008 to October 2013
and April 2016 to October 2016 and Etest (bioMérieux, Marcy l’Etoile, France) from November
2013 to March 2016. Receipt of concurrent
nephrotoxins within 5 days of receiving the loading dose was classified as the receipt of any of the
following: angiotensin converting enzyme inhibitors, angiotensin receptor blockers, intravenous
(IV) acyclovir, aminoglycosides, amphotericin B,
colistin, foscarnet, non-steroidal anti-inflammatory drugs, polymyxin B, sulfamethoxazole/trimethoprim, IV tacrolimus, and piperacillin/
tazobactam. The study was approved by the
Institutional Review Board at the University of
Kentucky (#54961) with a waiver of informed
consent given the study design.
Statistical analysis
Based on prior studies of MRSA infections suggesting clinical failure rates as high as 41%,10,11
and assuming a higher percentage due to the
requirement for critical illness in our study, we
anticipated a baseline clinical failure of 60%. In
order to detect a 20% decrease in the clinical failure, we determined that 97 patients were required
in each group (194 patients in total) to achieve
80% power with an α = 0.05 for the primary composite outcome.
Descriptive statistics were used to summarize categorical variables as percentages and continuous
variables as medians (interquartile ranges).
Independent samples were compared using the
journals.sagepub.com/home/tai

chi-square test or Wilcoxon rank-sum test as
appropriate. Given the relatively high frequency
of death anticipated from studying critically ill
patients, we analyzed time to ICU discharge from
vancomycin initiation with a competing-risks
regression approach using the methods of Fine
and Gray16 with death as a competing event and
displayed graphically with a cumulative incidence
function. Analysis of clinical failure by primary
infection site (isolated bacteremia or pneumonia)
between the loading dose and no loading dose
groups was a pre-planned secondary analysis.
Exploratory analyses of the primary outcome
included the reconstruction of the loading dose
variable in quartiles rather than a dichotomous
variable, and evaluation of initial doses of
⩾1750 mg versus <1750 mg as hypothesized by
other research groups to have benefit.10 We built
a multivariable logistic regression model for the
composite outcome of clinical failure using the
following pre-specified variables with complete
data present identified by the study team with the
potential to influence either the receipt of a loading dose or the outcome of clinical failure at the
time the vancomycin loading dose was administered: vancomycin initial dose (as a continuous
mg/kg variable), age, sex, MRSA culture site,
chronic or end-stage renal disease, ICU service,
day 1 maximum values for WBC, blood urea
nitrogen, serum creatinine, and temperature,
SOFA score, need for vasopressor support, or
need for mechanical ventilation. The PBS was
not included due to presumed collinearity with
SOFA and other variables included. Variance
inflation factors were used to assess collinearity
and ensure all variables were appropriate to retain
in the model. Statistical analyses were performed
in Stata (StataCorp. 2019. Stata Statistical
Software: Release 16. College Station, TX, USA:
StataCorp LLC) and SAS (SAS Institute Inc.,
Cary, NC, USA). Statistical significance was set
at p < 0.05.
Results
As shown in Figure 1, 871 patients were identified as having an ICU admission with a concurrent positive culture for MRSA during the
specified ICU admission. Following application
of the exclusion criteria, 449 patients were available for analysis. Of these patients, 103 (22.9%)
received a loading dose while 346 (77.1%) did
not. Patient demographics for the cohort are
shown in Table 1. The cohort consisted primarily
3
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Figure 1. Application of inclusion and exclusion criteria.

ICU, intensive care unit; MRSA, methicillin-resistant Staphylococcus aureus.

of patients on medical services with approximately half of MRSA cases isolated from respiratory cultures. Approximately three-quarters of the
cohort required mechanical ventilation and onethird required vasopressor support at the time of
vancomycin initiation. Patients were wellmatched in terms of baseline characteristics
between the two groups. Patients in the loading
dose group received higher initial doses on a milligram [1500 (1250–1750) versus 1250 (1000–
1500); p < 0.001] and a milligram per kilogram
actual body weight basis [21 (20–22) versus 16
(15–18); p < 0.001] compared with the no loading dose group. Patients classified as receiving a
loading dose tended to weigh less than patients in
the no loading dose group [68 (61–85) kg versus
80 (66–97) kg; p < 0.001]. Only one patient
received an initial vancomycin dose greater than
2 g. All patients were administered vancomycin
via intermittent infusion.
There was no difference in the percentage of
patients experiencing clinical failure between the
loading dose and no loading dose groups (74.8%
versus 72.8%; p = 0.698), with no significant difference between groups in any component of the
composite outcome (Table 2). No differences
were noted between groups in any of the secondary outcomes, including all-cause ICU mortality,
AKI, or duration of vasopressor or mechanical
ventilatory support. The first serum vancomycin
trough concentration was slightly higher in the
loading dose group, but this did not reach

4

statistical significance [15.6 (11.0–24.4) µg/ml
versus 14.0 (9.5–21.0) µg/ml; p = 0.056]. There
were no differences in WBC or maximum temperature on days 2–5 following the initiation of
vancomycin (Supplemental material eTable 1
online; Figure 2). In a simple competing risk
regression model with death as a competing
event, use of a loading dose was not associated
with time to ICU discharge from vancomycin initiation (subdistribution hazard ratio 1.09; 95%
confidence interval 0.86–1.40). The cumulative
incidence function is shown in Supplemental
eFigure 1. In the subgroup of patients with isolated MRSA bacteremia, there was no difference
in clinical failure between the loading dose and no
loading dose groups: 30/34 (88.2%) versus 63/80
(78.8%); p = 0.232. Similarly, in patients with
MRSA respiratory cultures (with or without bacteremia), there were no differences between loading dose and no loading dose groups: 47/69
(68.1%) versus 188/265 (70.9%); p = 0.647.
In exploratory analyses of the primary outcome,
the vancomycin dose (in milligrams per kilogram
actual body weight) was assessed in quartiles
rather than a dichotomous variable and there
were no significant differences in the frequency of
clinical failure (p = 0.794; Supplemental eTable 2).
Similarly, when initial doses of ⩾1750 mg were
compared with doses <1750 mg, there was no
difference in clinical failure between the two
groups (p = 0.485; Supplemental eTable3). In the
adjusted multivariable logistic regression model,

journals.sagepub.com/home/tai
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Table 1. Baseline demographics.
Patient demographic

Loading dose
n = 103

No loading dose
n = 346

p-value

Age, years

54 (38–66)

57 (45–68)

0.102

Sex (% male)

58 (56.3)

198 (57.2)

0.869

Culture site

0.099

Blood (%)

34 (33.0)

80 (23.2)

Respiratory (%)

55 (53.4)

199 (57.7)

Both (%)

14 (13.6)

66 (19.1)

Chronic kidney disease (%)

8 (7.8)

41 (11.9)

0.243

End stage renal disease (%)

7 (6.8)

23 (6.7)

0.958

Service (% medical)

80 (77.7)

234 (67.6)

0.051

Minimum inhibitory concentration, µg/mla

1 (1–1)

1 (1–1)

0.352

Long term indication for MRSA treatmentb (%)

12 (11.7)

25 (7.2)

0.216

Weight, kg

68 (61–85)

80 (66–97)

<0.001

Initial vancomycin dose, mg

1500 (1250–1750)

1250 (1000–1500)

<0.001

Initiatial vancomycin dose, mg/kg actual body
weight

21 (20–22)

16 (15–18)

<0.001

Number of concurrent nephrotoxins within first
5 days

1 (0–2)

1 (1–2)

0.441

Vancomycin therapy duration, days

6 (3–12)

6 (3–11)

0.843

White blood cell count, ×103/mm3

15 (10–21)

13 (9–19)

0.150

Blood urea nitrogen, mg/dl

23 (15–41)

26 (15–41)

0.625

Serum creatinine, mg/dl

1.1 (0.7–1.6)

1.0 (0.7–1.7)

0.902

Maximum temperature, °F

100.4 (98.7–102.0)

100.7 (99.3–102.3)

0.101

Sequential organ failure assessment score

8 (5–10)

7 (5–10)

0.674

Pitt bacteremia score

5 (4–7)

5 (3–7)

0.607

Requirement for vasopressor support (%)

31 (30.1)

105 (30.4)

0.961

Mechanical ventilation (%)

77 (74.8)

254 (73.6)

0.818

1.8 (1.1–3.3)

1.6 (1.1–3)

0.586

At time of vancomycin initiation

Lactate,

mmol/lc

aAvailable

for 295 patients.
indication defined as ⩾4 weeks of therapy.
cAvailable for 366 patients.
MRSA, methicillin-resistant Staphylococcus aureus.
bLong-term

journals.sagepub.com/home/tai
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Table 2. Study outcomes.
Outcome

Loading dose
n = 103

No loading dose
n = 346

p-value

Clinical failure (%)

77 (74.8)

252 (72.8)

0.698

Death within 30 days (%)

20 (19.4)

77 (22.3)

–

Blood cultures positive ⩾7 days (%)

12 (11.7)

16 (4.6)

–

WBC count >12 × 103/mm3 after 5 days (%)

28 (27.2)

93 (26.9)

–

Persistent temperature >100.4°F after 5 days (%)

8 (7.8)

36 (10.4)

–

Substitution/addition of alternative treatment (%)

9 (8.7)

30 (8.7)

–

All-cause mortality in ICU (%)

21 (20.4)

87 (25.1)

0.321

Time from vancomycin initiation to ICU discharge, days

9.4 (4.4–16.7)

9.5 (4.9–17.4)

0.880

20 (20.2)

59 (17.8)

0.765

Duration of vasopressor support, daysb

3 (2–5)

3 (2–6)

0.793

Duration of mechanical ventilation, daysc

8.5 (4.3–17)

9 (4–20)

0.632

First vancomycin serum trough concentration, µg/mld

15.6 (11.0–24.4)

14.0 (9.5–21.0)

0.056

Primary outcome

Secondary outcomes

 Acute kidney injury within 5 days of vancomycin
initiation (%)a

aPatients

with end stage renal disease excluded from assessment.
for the 136 patients requiring vasopressor support at vancomycin initiation.
cAvailable for the 331 patients requiring mechanical ventilation at vancomycin initiation.
dAvailable for 361 patients.
ICU, intensive care unit; WBC, white blood cell.
bAvailable

6

the first dose of vancomycin (expressed in milligrams per kilogram as a continuous variable) was
not associated with clinical failure: odds ratio
0.98 (95% confidence interval 0.91–1.06)
(Supplemental eTable 4).

bacteremia specifically,18 obtaining informed
consent during this window for a definitively large
study in critically ill patients is likely to hinder
such a trial ever being done, particularly for confirmed MRSA infection rather than all patients
receiving empiric vancomycin.

Discussion
This represents the first study to our knowledge
to assess clinical outcomes associated with vancomycin loading doses recommended by consensus
guidelines in critically ill patients with MRSA
infection,7 and the largest study of vancomycin
loading doses in any patient population. While
the ideal design to answer this clinical question is
a randomized controlled trial, given the literature
that every hour delay in antibiotics in a patient
with sepsis is associated with a 7.6% reduction in
survival,17 including similar literature in S. aureus

A randomized controlled trial of vancomycin
loading doses in the emergency department
showed that a loading dose of 30 mg/kg versus
15 mg/kg resulted in higher trough values at 12
and 24 h, but not by 36 h, with no significant difference in AKI or clinical outcomes between the
two groups.19 Similarly, other observational studies have shown an association between loading
doses and higher target attainment of initial
trough values without increasing the risk of
AKI,20,21 although improved target trough attainment is not consistent across the literature.11,22

journals.sagepub.com/home/tai
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Figure 2. Daily white blood cell count and temperature trends.

Similar to other studies, we did not observe any
increased risk of AKI with use of a vancomycin
loading dose.19,20 Particularly with updated consensus guidelines recommending AUC assessment
at this juncture rather than trough assessment,7 the
existing literature linking vancomycin loading
doses to trough attainment as justification for use
of a particular dosing strategy deserves reevaluation. Thus, there is an increasing importance to
evaluate clinical outcomes regarding the decision
to administer a loading dose.
One small cohort study found an association of
vancomycin loading doses (⩾20 mg/kg) with clinical response, as defined by survivors with a
⩾30% reduction in WBC count or C-reactive
protein, or decline in fever over 48–72 h; however, the number of MRSA cases from the cohort
studied was relatively small.11 In a larger study of
MRSA bacteremia, loading doses (⩾20 mg/kg)
were not associated with treatment failure; however, in a post-hoc analysis where loading doses
were reclassified as ⩾1750 mg, a protective effect
of loading doses was noted.10 In both studies,
loading doses were not associated with nephrotoxicity.10,11 Of note, critically ill patients were
not the focus of these prior studies, and ICU
patients constituted approximately 25% of the
cohort.10 Our study did not find a benefit of loading doses on any of the distinct outcomes that we
included in the primary composite outcome, nor
when assessed by site of infection as a subgroup
analysis. Similarly, there was no signal of benefit
noted in the sensitivity analysis examining

journals.sagepub.com/home/tai

quartiles of loading doses, the reclassification of
loading doses as 1750 mg or higher, or in the multivariable logistic regression model evaluating initial dose on a milligrams per kilogram basis as a
continuous variable.
As noted previously, a recent survey of vancomycin dosing practices in critically ill patients
revealed that a lack of clinical outcome data, concerns of nephrotoxicity, and time delay of admixed
custom doses from the pharmacy (in the case of a
loading dose) versus pre-mixed drug from automated dispensing cabinets limited application of
loading doses in all cases.8 Our data suggest loading doses of vancomycin do not increase the risk
of AKI, even in critically ill patients with multiple
risk factors for AKI. However, the data also suggest no clinical benefit of loading doses even in
confirmed MRSA infections in critically ill
patients, thus supporting the noted clinician hesitation. Indeed, given the increase in mortality
with every hour delay in antibiotic therapy,17,18
our study supports the notion that therapy should
not be delayed for dose customization to meet the
specified loading dose criteria. This finding not
only applies to emergency departments, postanesthesia care units, and other ICU triage areas
in resource-intensive healthcare settings, but may
also be a relevant consideration to care provisions
in lower resource-intensive settings where dose
customization for loading doses may be limited.
Although the mechanistic explanation of our
findings is less clear for patients with bacteremia,
the relatively poor ability of vancomycin to

7
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concentrate in pulmonary tissue, particularly after
a single dose, may explain the lack of difference in
clinical outcomes observed in our study.23
Additionally, considering the literature associating a delay in second dose of antibiotics for
patients admitted from the emergency department with sepsis with outcomes including mortality,24 our study suggests that the initial, loading
dose of vancomycin may not significantly influence clinical outcomes in critically ill patients,
and a greater emphasis be placed on ensuring
timely initiation of subsequent doses to ensure
appropriate efforts to attain goal AUC:MIC targets for the initial 24 h period.
Strengths of our study included the large sample
size, which was sufficiently powered to determine
differences in clinical failure. We built on previous literature by studying only confirmed cases of
MRSA and expanding on the study of pharmacokinetic outcomes to clinical outcomes of this
patient population. Our definition of clinical failure has been used in other studies of MRSA
infection and all components are measured objectively, thus not relying on subjective assessments
such as clinical resolution.10,11 Anticipating that
detecting a difference in an outcome such as ICU
length of stay or vasopressor duration would
require several-fold additional patients, the outcome of clinical failure is sensitive to surrogate
outcomes such as WBC and temperature changes
over time that may have seen more immediate
effects from the loading dose, if present. The two
groups of patients were similar in terms of severity of illness, kidney disease, and other pre-identified factors that might have predisposed to receipt
of a loading dose or clinical outcome. We also
included multiple types of infections commonly
afflicting critically ill patients.
Our study also has noted limitations, including
the retrospective, non-randomized, and single
center design. Due to vancomycin dosing practices at the institution, we are not able to make
any inferences about the clinical benefits of loading doses beyond 2000 mg as only one patient
received a >2000 mg loading dose. However, a
dose cap of 2000 mg was the most commonly
reported dose cap in a prior study of vancomycin
dosing practices among critical care pharmacists,
suggesting this practice is widespread.8 Relevant
to this study, any patient over 100 kg was therefore essentially ineligible to be categorized as

8

having received a loading dose. Accordingly,
whether or not relatively larger loading doses (up
to 3000 mg as maximally defined in current consensus guidelines)7 are associated with any clinical benefit remains unknown at this time, although
the lack of dose response noted in the exploratory
analysis of loading dose by quartiles would suggest against this. Our study design also excluded
patients weighing ⩾125 kg, thus our results may
not be directly applicable to obese patients. The
difference in the initial vancomycin dose between
the loading dose and no loading dose cohorts was
not as drastic as would have been the case if
higher loading doses were used in our study. The
loading dose group received an additional 5 mg/
kg (or 250–500 mg typically). While dichotomization of information can have drawbacks, use of a
loading dose or not is typically a dichotomous
decision clinically. Additionally, the lack of signal
in the quartile analysis and in the multivariable
regression where initial dose was analyzed as a
continuous variable supports the findings that initial dose does not appear to impact clinical failure. We also did not estimate or measure
vancomycin AUC in these groups as a result of
the loading dose, or in subsequent dosing intervals, and thus are unable to directly compare vancomycin AUC with these clinical outcomes. The
known variability in vancomycin pharmacokinetics in critically ill patients makes it possible that
patients in this study may have not achieved adequate AUC with the loading doses, thus explaining the lack of clinical benefit observed. For
example, a significant number of these patients
may have had AKI upon admission or been
actively fluid resuscitated at the time of vancomycin loading dose, which would have increased the
Vd and may have influenced the ability to achieve
the target exposure with the vancomycin doses
observed in the study. More patients had respiratory infections than bacteremia, thus if there was
a differential effect of loading doses given the site
of infection, we may have been underpowered to
detect it. Finally, although patients appeared to
be well-matched based on identified characteristics, we cannot rule out residual confounding and
its effects.
Conclusion
In critically ill patients with MRSA infection cultured from the blood or respiratory tract, receipt
of a loading dose of vancomycin (⩾20 mg/kg
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actual body weight) was not associated with any
differences in clinical failure, mortality, ICU
length of stay, AKI, or other outcomes when compared with patients not receiving a loading dose.
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